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Abstract: We have previously reported cyclic cell-penetrating peptides [WR]5 and [WR]4 as molecular
transporters. To optimize further the utility of our developed peptides for targeted therapy in cancer
cells using the redox condition, we designed a new generation of peptides and evaluated their
cytotoxicity as well as uptake behavior against different cancer cell lines. Thus, cyclic [C(WR)xC] and
linear counterparts (C(WR)xC), where x = 4–5, were synthesized using Fmoc/tBu solid-phase peptide
synthesis, purified, and characterized. The compounds did not show any significant cytotoxicity
(at 25 µM) against ovarian (SK-OV-3), leukemia (CCRF-CEM), gastric adenocarcinoma (CRL-1739),
breast carcinoma (MDA-MB-231), and normal kidney (LLCPK) cells after 24 and 72 h incubation. Both
cyclic [C(WR)5C] and linear (C(WR)5C) demonstrated comparable molecular transporter properties
versus [WR]5 in the delivery of a phosphopeptide (F′-GpYEEI) in CCRF-CEM cells. The uptake
of F′-GpYEEI in the presence of 1,4-dithiothreitol (DTT) as the reducing agent was significantly
improved in case of l(C(WR)5C), while it was not changed by [C(WR)5C]. Fluorescence microscopy
also demonstrated a significant uptake of F′-GpYEEI in the presence of l(C(WR)5C). Cyclic [C(WR)5C]
improved the uptake of the fluorescent-labeled anti-HIV drugs F′-d4T, F′-3TC, and F′-FTC by
3.0–4.9-fold. These data indicate that both [C(WR)5C] and linear (C(WR)5C) peptides can act as
molecular transporters.
Keywords: cell-penetrating peptide; cancer; cytotoxicity; cellular uptake; disulfide bridge; drug
delivery; phosphopeptide
1. Introduction
Efficient molecule translocation across the cell membrane remains a major obstacle for intracellular
cargo delivery. The cell membrane is made of mucopolysaccharides and phospholipids that are
negatively charged and very hydrophobic. The nature of the cell membrane makes it very impermeable
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for many water-insoluble or negatively-charged molecules. For example, phosphopeptides are used
as probes for studying phosphoprotein–protein interactions; the major challenge is to transport this
negatively charged molecule into the cells [1–3]. Furthermore, a variety of anticancer and anti-HIV
agents have limited therapeutic applications due to poor cellular uptake. Translocation of cell
impermeable compounds, such as phosphopeptides, into cells requires vectors that facilitate cell
binding and internalization. The development of highly effective cellular delivery systems to enhance
the delivery of biologically important cargos has become an urgent need. Numerous delivery systems
have been explored, such as liposomes and micelles. While important progress in cargo delivery has
been made with these various vectors, none of them are optimal [4,5].
Recently, the use of cell-penetrating peptides (CPPs) in drug delivery has dramatically increased
in basic research and preclinical studies [6–8]. CPPs have been shown to facilitate the passage of
different cargos across the cell membrane, enhance the cellular uptake of the drugs and afford improved
bioactivity. CPPs are efficient cellular uptake vectors, due to their low toxicity, physiological stability,
and efficiency for rapid delivery into cells [9,10]. Depending on their physicochemical properties,
CPPs can be cationic, amphipathic, or hydrophobic [11]. Amphipathic CPPs’ sequences contain an
alternating pattern of polar and non-polar regions. Poly-arginine peptides display the highest level
of cellular uptake due to the presence of the guanidine unit that has a tendency to form bidentate
hydrogen bonding with the negatively-charged moieties, such as the carboxylic, sulfate, and phosphate
groups of cell membrane proteins in mucopolysaccharides and phospholipids, respectively, leading to
cellular internalization of peptides under physiological conditions [12]. Besides arginine, the presence
of other amino acids has shown an efficient enhancement of cellular uptake. The addition of four
tryptophan residues to a CPP’s sequence has shown to improve its cellular internalization [13].
Positively charged CPPs bind to the cell surface via electrostatic interaction with proteoglycans
called glycosaminoglycans (GAG), which are negatively charged and presented everywhere in the cell
membranes and form a platform that connects CPPs or the CPP/cargo complex to the extracellular
matrix [14–16]. The secondary structure, number, location of arginine in the CPP’s sequence, and the
chirality of amino acids are the main factors associated with enhanced uptake efficiency [17–21].
Cyclic CPPs are a unique emerging class of conformationally constrained peptides with a higher
metabolic stability and binding specificity to their targets. The cyclization of linear peptides reduces
the degree of freedom, and this constrained structure provides specificity for their target and higher
binding affinity. These cyclic CPPs permeate the membrane through a number of different mechanisms,
and some may require multiple pathways [22]. The properties of amino acids in cyclic CPPs provide
unique membrane permeability and transporter properties [23]. Prior studies showed that cyclic
amphipathic peptides composed of alternative tryptophan (W) and arginine (R) residues, [WR]4 and
[WR]5, enhanced the cellular uptake of some cell-impermeable compounds, such as anti-HIV drugs,
doxorubicin, phosphopeptides, and siRNA, or generated peptide nanostructures [23–28] by us and
others [22]. Cyclic peptides have high stability towards proteolytic degradation and more efficiency
for cargo delivery due to the rigidity of cyclic peptides [28].
In continuation of our efforts to develop a structure–cellular uptake relationship for cyclic peptides
composed of tryptophan and arginine residues, herein we designed a modification to our previously
developed peptide with disulfide cyclization as a new generation of peptides and evaluated their
cytotoxicity and cellular uptake against different cancer cell lines. The rationale of current studies was
that cancer cells have a higher percentage of glutathione as compared with normal cells [29,30]. Thus,
disulfide bonds can be reduced in cancer cells significantly higher than normal cells, providing the
selective delivery of anticancer drugs to cancer cells.
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2. Results and Discussion
2.1. Chemistry
Four linear and cyclic peptides were synthesized using Fmoc/tBu solid-phase peptide synthesis
(Figure 1). These series of peptides were designed to determine the impact of the changes in the
cyclization strategy on the cellular uptake and cytotoxicity. The synthetic procedure for the synthesis
of l(C(WR)4C) and c[C(WR)4C] is shown in Scheme 1 as representative examples. Parentheses () and
brackets [] represent the linear and cyclic peptides, respectively. Further, letters l and c represent
linear and cyclic peptides, respectively. The linear peptide containing alternative tryptophan (W)
and arginine (R) amino acids with two cysteines (C) residues (CWRWRWRWRC) was assembled on
the cysteine preloaded chlorotrityl resin using coupling and deprotecting reagents as depicted in
Scheme 1. The linear peptide was completely cleaved in the presence of a freshly prepared cleavage
cocktail containing trifluoroacetic acid (TFA)/thioanisole/1,2-ethanedithiol (EDT)/anisole (90:5:3:2,
v/v/v/v) to afford l(C(WR)4C). The linear peptide was subjected to an oxidation reaction using a 10%
DMSO-H2O solution over 24 h at room temperature to afford a disulfide-linked cyclic peptide. Peptides
were characterized and purified using matrix-assisted laser desorption/ionization (MALDI) mass
spectroscopy and reverse-phase high-performance liquid chromatography (RP-HPLC), respectively.
The analytical HPLC data (in Supplementary Materials) showed a retention time (RT) of 9.6 and 9.8 min
for the linear peptides (C(WR)4C) and (C(WR)5C), respectively, while the RTs for cyclic peptides
[C(WR)4C] and [C(WR)5C] were 10.3 and 10.5 min, respectively.
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Figure 1. Chemical structures of synthesized peptides. Figure 1. Chemical structures of synthesized peptides.
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Sche e 1. t esis of l( ( )4 ) ( ) [ ( ) ] ( ) t ti l .
2.2. In Vitro Cytotoxicity Assay of Peptides
To evaluate the cytotoxicity of synthesized linear (C(WR)xC) and cyclic [C(WR)xC] (x = 4–5)
peptides, a cell viability assay was employed using kidney (LLC-PK1), leukemia (CCRF-CEM), gastric
adenocarcinoma (CRL-1739), breast cancer cell line MDA-MB-231, and ovarian SKOV-3 cell lines at
concentrations of 5, 10, 25, and 50 µM at 24 and 72 h (Figures 2–6). Doxorubicin (Dox, 5 µM) was used
as a positive control. The percentage of cell survival demonstrated that Dox was cytotoxic even at 5 µM.
l(C(WR)5C) reduced the cell proliferation by 40% and 49%, respectively, after 24 and 72 h incubation
in LLC-PK1 cells (at 50 µM), while cell proliferation was reduced with c[C(WR)5C] by 53% and 56%,
respectively, after 24 h and 72 h incubation (at 50 µM) (Figure 2). Both l(C(WR)5C) and c[C(WR)5C]
showed significant toxicity at 50 µM in CCRF-CEM cells (reduced the cell proliferation by 38% and 51%
after 24 h and 27% and 38% after 72 h incubation, respectively) (Figure 3). There was a 48% reduction
in cell proliferation in CRL-1739 after 24 h incubation of c[C(WR)4C], while the other compounds did
not show any significant toxicity at 5–50 µM (Figure 4). All the peptides did not show any significant
toxicity in SK-OV-3 cells (Figure 5) and MDA-MB-231 (Figure 6) at the tested concentrations. Based on
these data, a nontoxic concentration of synthesized peptides at 25 µM was selected to evaluate the
cellular uptake studies.
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2.3. Cellular Uptake Studies
2.3.1. Cellular Uptake of Fluorescent-Labeled Compounds in the Presence of Synthesized Peptides
Phosphopeptides are important signaling ligands that are used for the understanding of the
activation of different proteins in the cellular processes [31]. However, the phosphopeptides are
negatively-charged molecules and are unable to cross the membrane. The SH2 domain ligand of Src
tyrosine kinase receptor GpYEEI was found to be an optimal ligand to understan the activation
of Src kinase. Therefore, we previously used a fluorescent-labeling version of this phosphopeptide
(F′-GpYEEI) for the cellular uptake studies [25]. A nontoxic concentration of synthesized peptides at
25 µM was selected to evaluate the cellular uptake of F′-GpYEEI (5 µM) (F’ = 5(6)-carboxyfluorescein)
in CCRF-CEM and MDA-MB-231 cell lines after incubation for 3 h using a fluorescence-activated
cell sorter (FACS) analysis. The positive and negative controls were cyclic peptide [WR]5 at 25 µM
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and F′-GpYEEI, respectively (Figure 7). A 7-fold enhancement of the cellular uptake of F′-GpYEEI
was detected for both l(C(WR)5C) and c[C(WR)5C], which were comparable to our previous peptide
[WR]5 in the CCRF-CEM cell line. c[C(WR)4C]) did not show any significant improvement in the
cellular uptake of F′-GpYEEI in comparison with [WR]5, l(C(WR)5C), or c[C(WR)5C], while l(C(WR)4C)
improved the uptake approximately by 4.6-fold.
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Figure 7. Fluorescence-activated cell sorter (FACS) analysis of F′-GpYEEI (5 µM) using l(C(WR)5C)
and c[C(WR)5C] at 25 µM in CCRF-CEM cells after 3 h incubation (n = 3) (if p < 0.05 then *, if p < 0.01
then **, if p < 0.001 then ***, if p < 0.0001 then ****). Error bars are SD.
Peptides l(C(WR)5C) and c[C(WR)5C] also improved the cellular uptake of F′-GpYEEI (5 µM)
significantly in MDA-MB-231 cells. 1,4-Dithiothreitol (DTT) (2 mM) was used to act as the reducing
agent of the disulfide bond. Here, the presence of DTT with c[C(WR)5C] did not improve the uptake
of F′-GpYEEI. On the other hand, the cellular uptake was significantly enhanced in the presence
of l(C(WR)5C) and DTT (Figure 8), suggesting that the upt ke was not dependent on the reduction
of the disulfide bridge. The role of DTT in improving the uptake of th li ear peptid could be
due to the formation of t disulfide bond with the free thiol (SH) groups, generating a different
molecular tr nsporter.
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Figure 8. FACS analysis of the uptake of F′-GpYEEI (5 µM) using synthesized peptides l(C(WR)5C)
and c[C(WR)5C] t 25 µM in MDA-MB-231 cells after 3 h incubatio in the presence and absence of
DTT. NT stands for “No treatment”, n = 3, if p < 0.05 then *, if p < 0.01 then **, if p < 0.001 then ***,
if p < 0.0001 then ****. E ror bars are SD.
We have previously reported that [WR]5 improves the delivery of anti-HIV drugs such as stavudine
(d4T), lamivudine (3TC), and emtricitabine (FTC) [17]. The fluorescent-labeled conjugate of these
dr gs, F′- , F′-3TC, and F′-FTC, wer used to determine their cellular uptake in the MDA-MB-231
cell line in the presence of l(C(WR)5C) and c[C(WR)5C] (Figure 9). The physical mixture of the drug
(F′-3TC, 5 µM) with both peptides improved the uptake of the drug in the range of 4.0–4.8-fold. The
uptake of F′-d4T (5 µM) was increased when physically mixed with c[C(WR)5C]) at 25 µM by 4.9-fold,
while l(C(WR)5C) was not significantly effective. c[C(WR)4C]) at 25 µM enhanced the uptake of F′-FTC
(5 µM) by 3-fold, while l(C(WR)5C was not effective. Based on these data, the modified peptides were
still effective in enhancing the uptake of the anti-HIV drugs, but the improvement was less than that of
fluorescent-labeled phosphopeptide in the MDA-MB-231 cell line.
In order to understand the mechanism of cellular transportation, the cellular uptake of the
fluorescent-labeled phosphopeptide was examined in the presence of l(C(WR)5C) and different
endocytic inhibitors. However, no significant change in the phosphopeptide uptake was observed in
the presence of β-cyclodextrin, chlorpromazine, and chloroquine after 3 h incubation, thus eliminating
the possibility of clathrin-mediated or caveolae-mediated endocytosis. A comparable uptake was also
observed in the presence of sodium azide, suggesting energy-independent endocytosis (Figure 10).
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Figure 10. FACS analysis of the uptake of F′-GpYEEI (5 µM) using synthesized peptide l(C(WR)5C)
(25 µM) in the presence of different endocytic inhibitors in MDA-MB-231 cells after 3 h incubation
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Molecules 2020, 25, 2581 12 of 17
2.3.2. Fluorescence Microscopy
The modified and parent peptides l(C(WR)5C), c[C(WR)5C], and [(WR)5] were used at 25 µM
to monitor the cellular uptake of F′-GpYEEI (5 µM) using fluorescence microscopy in CCRF-CEM
cells. Figure 11 shows the intracellular/cellular localization of the peptides in CCRF-CEM cells after 3 h
incubation at 37 ◦C. l(C(WR)5C) demonstrated a significant uptake of F′-GpYEEI, while the uptake
was less obvious in the presence of c[C(WR)5C]. These data indicate that these modified peptides have
different molecular transporter properties in transporting F′-GpYEEI across the cellular membrane.
The exact localization of the peptides needs further investigation.Molecules 2020, 25, x 14 of 19 
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3. Conclusions
A series of linear and cyclic peptides l(C(WR)4C), l(C(WR)5C), c[C(WR)4C], and c[C(WR)5C]
were synthesized after the incorporation of cysteine- and disulfide-assisted cyclization, respectively,
to compare the cellular uptake property with the previously synthesized peptide [WR]5. The
synthesized peptides were found nontoxic at a 5–25 µM concentration in SK-OV-3, CCRF-CEM, and
MDA-MB-231 cells. Peptides l(C(WR)5C) and c[C(WR)5C] improved the cellular uptake of F′-GpYEEI
by approximately 7-fold, which was comparable to that of [WR]5. The uptake of the fluorescence-labeled
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phosphopeptide was endocytosis-independent. The delivery of small molecule drugs like d4T, 3TC,
and FTC was also improved by 4.0–4.9-fold in the presence of cyclic peptides (c[C(WR)4C] and
c[C(WR)5C]), whereas the linear peptide did not significantly improve the uptake. These data indicate
that these peptides have a cell permeation property and could be used in transporting appropriate
cargo molecules across the cellular membrane. The delivery of cargo by the cyclic peptide c[C(WR)5C]
was not dependent on the reduction of the disulfide bridge. This work advances the scientific
knowledge in the area of the peptide-based delivery system for improving the cellular uptake of
cell-impermeable compounds.
4. Materials and Methods
4.1. Materials
Cysteine-loaded 2 chlorotrityl resin (H-Cys(Trt)-2Cl-Trt resin) and Fmoc-amino acid building
blocks were obtained from AAPPTec (Louisville, KY, USA). Chemical reagents and solvents were
purchased from MilliporeSigma (Milwaukee, WI, USA) and used without further purification. Final
products were purified using an RP-HPLC system (LC-20AP) from Shimadzu (Canby, OR, USA), with
a gradient system of acetonitrile and water with 0.1% TFA (v/v), and a reversed-phase preparative
column (Waters XBridge, BEH130, 10 µm, 110 Å, 21.2 × 250 mm), with a flow rate of 8 mL/min and
detection at 214 nm. The analytical RP-HPLC system (LC-20ADXR) from Shimadzu (Canby, OR, USA)
was used with a gradient system of acetonitrile and water with 0.1% TFA (v/v) using a VyDAC column
(218TP54, 5 µm, 4.60 × 150 mm), with the flow rate of 1 mL/min and detection at 220 nm. The chemical
structures of the final peptides were elucidated using a high-resolution MALDI-TOF (model # GT 0264
from Bruker Inc, Fremont, CA, USA) with α-cyano-4-hydroxycinnamic acid as a matrix in the positive
mode. Fluorescence-labeled phosphopeptide (F′-GpYEEI)[25] and fluorescence-labeled anti-HIV
drugs [2′,3′-dideoxy-5-fluoro-3′-thiacytidine (FTC) and 2′,3′-didehydro-2′,3′-dideoxythymidine
(d4T), and fluorescence-labeled lamivudine (3TC)] were prepared and characterized according
to the previously reported procedures [32–36]. [WR]5 was prepared according to the previously
reported procedure by us [24]. Human leukemia carcinoma cell line (CCRF-CEM, ATCC no.
CCL-119), ovarian cancer cell line (SK-OV-3, ATCC no. HTB-77), gastric adenocarcinoma (AGS,
ATCC no. CRL-1739), breast carcinoma (MDA-MB-231, ATCC no. HTB-26), and normal
kidney cell line (LLC-PK1, ATCC no. CRL-1392) were purchased from American Type Culture
Collection (ATCC, Manassas, VA, USA). CellTiter 96® AQueous MTS Reagent Powder was
purchased from Promega (Madison, WI, USA). This reagent consists of a tetrazolium compound
(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (named
MTS) and phenazine ethosulfate (PES) for the cell proliferation studies. All the cell culture materials
were purchased from Fischer Scientific (Hanover Park, IL, USA).
4.2. Chemistry
4.2.1. Synthesis of Linear Peptides (C(WR)4C) and (C(WR)5C)
H-Cys(Trt)-2Cl-Trt resin and Fmoc-protected amino acids were used as building blocks for the
synthesis of peptides on a scale of 0.3 mmol. 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium
hexafluorophosphate (HBTU)/N,N-diisopropylethylamine (DIPEA) were used as the coupling and
activating reagents, respectively. Piperidine in N,N-dimethylformamide (DMF) (20%, v/v) was used
for the Fmoc deprotection. H-Cys(Trt)-2Cl-Trt resin (0.3 meq/g, mg) was swelled in DMF under dry
nitrogen (15 min × 3 times). The solvent was filtered off. The next Fmoc-protected amino acid (0.9
mmol, 3 equiv.) was coupled to the N-terminal of the cysteine in the presence of (HBTU) (0.9 mmol,
3 equiv., 342 mg), and (DIPEA) (1.2 mmol, 6 equiv., 315 µL) in DMF (15 mL) by agitation under dry
nitrogen for 1.5 h. The reaction solution was filtered off after the completion of the coupling. The
resin was washed with 15 mL DMF (2 × 5 min). Deprotection of Fmoc was performed by using a
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20% piperidine/DMF solution (v/v, 10 mL, 2 × 15 min). The reaction solution was filtered off, and
the resin was washed with DMF (15 mL, 2 × 5 min). The subsequent amino acids were coupled and
deprotected in a similar manner. Fmoc deprotection was performed on the last amino acid. The resin
was washed with DMF (15 mL, 2 × 5 min). The resultant peptides were cleaved from the resin using a
cleavage cocktail of TFA/thioanisole/EDT/anisole (90:5:3:2, v/v/v/v) for 3 h. The crude products were
precipitated by the addition of cold diethyl ether purified by RP-HPLC using a gradient of 0–90%
acetonitrile (0.1% TFA) and water (0.1% TFA) over 60 min with a C-18 column. Purified peptides were
lyophilized to yield a white powder (100 mg). The chemical structures of the peptides were elucidated
using a matrix-assisted laser desorption/ionization (MALDI) time-of-flight (TOF) analyzer.
MALDI-TOF (m/z) for (C(WR)4C) (1), [C74H100N26O11S2]: calcd,1592.7506; found, 1592.7797 [M]+.
MALDI-TOF (m/z) for (C(WR)5C) (2), [C91H122N32O13S2]: calcd,1934.9311; found, 1934.2925 [M]+.
4.2.2. Synthesis of Cyclic Peptides ([C(WR)4C], [C(WR)5C])
The linear peptides (1 or 2) (30 mg) were dissolved in a 10% DMSO-H2O solution (150 mL)
using a 250 mL round-bottomed flask. The reaction mixture was stirred in open air for 24 h at room
temperature. After the reaction completion as confirmed by the MALDI-TOF mass spectroscopy, the
resultant solution was concentrated in a rotatory evaporator to half of its amount. The reaction mixture
was further injected directly in RP-HPLC using a gradient of 0–90% acetonitrile (0.1% TFA) and water
(0.1% TFA) over 60 min with a C-18 column. Purified peptides were lyophilized to yield a white
powder (20 mg).
MALDI-TOF (m/z) for ([C(WR)4C] (3), [C74H98N26O11S2]: calcd, 1590.7350; found, 1590.8999 [M]+.
MALDI-TOF (m/z) for [C(WR)5C]) (4), [C91H120N32O13S2]: calcd,1932.9154; found, 1932.9976 [M]+.
4.3. In Vitro Cytotoxicity Assay of Peptides
The in vitro cytotoxicity of the peptides was evaluated using the human leukemia carcinoma cell
line (CCRF-CEM), normal kidney cell line (LLC-PK1), gastric adenocarcinoma (CRL-1739), ovarian
(SKOV-3), and breast carcinoma (MDA-MB-231) cell lines to determine the toxicity of the peptides
according to the previously reported procedure [17]. CCRF-CEM cells were seeded at 50,000 cells in
0.1 mL per well in 96-well plates. Other cells were seeded at 5,000 cells in 0.1 mL per well in 96-well
plates. All cell lines were seeded in RPMI-1640 medium (pH 7.4) containing FBS (10%), 24 h prior to
the experiment. The compounds (aqueous solution of peptides) were added to each well in triplicate
at a concentration of 5–50 µM and incubated for 24 h and 72 h, respectively, at 37 ◦C in a humidified
atmosphere of 5% CO2. Cell culture medium and water were used as negative controls. The peptides
were dissolved in water; hence water was used as a negative control to normalize the results. After the
incubation period, 20 µL MTS reagent was added to each well followed by incubation of 2 h. The MTS
protocol is based on the reduction of MTS tetrazolium by the viable cells. This generates formazan
crystals which are soluble in cell culture medium and can be measured at 490 nm. Cell viability was
then determined by measuring the fluorescence intensity at 490 nm using a SpectraMaxM2 microplate
spectrophotometer (Molecular Devices, San Jose, CA, USA). The percentage of cell survival was
calculated as [(OD value of cells treated with the test mixture of compounds)−(OD value of culture
medium)]/[(OD value of control cells) − (OD value of culture medium)] × 100%.
4.4. Cellular Uptake Studies
CCRF-CEM and MDA-MB-231 cells were used to measure the cellular uptake of F′-GpYEEI,
fluorescent-labeled lamivudine (F’-3TC), fluorescent-labeled stavudine (F´-d4T), and fluorescent-labeled
emtricitabine (F´-FTC). FACS analysis was performed in order to measure the intracellular uptake
of the cargo and determine whether the presence of the peptide affects the uptake of F′-GpYEEI,
F´-3TC, F´-d4T, and F´-FTC. The fluorescence intensity was measured in the presence and absence of
the synthesized peptides. The cells (5 × 108 cells per well) were taken in 6-well plates in Opti-MEM
or serum-free RPMI medium. F′-GpYEEI, F´-3TC, F´-d4T, and F´-FTC at 5 µM were mixed with the
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synthesized peptides at 25µM for 30 min and added to the wells for 3 h of incubation at 37 ◦C. F′-GpYEEI
(5 µM), F´-3TC, F´-d4T, and F´-FTC alone (5 µM) were used as negative controls. Additionally, cell
culture medium and water were used as negative controls. The peptides were dissolved in water;
hence water was used as a negative control to normalize the results. After 3 h, cells were centrifuged
at 800 RPM, and the cells were collected as precipitant. Then, the cells were washed twice with
PBS. Finally, the cells were resuspended in flow cytometry buffer and analyzed by flow cytometry
(FACSCalibur: Becton, Dickinson & Co. (Franklin Lakes, NJ, USA)) using FITC channel and the
CellQuest software. The data presented were based on the mean fluorescence signal for 10,000 cells
collected. All assays were performed in triplicates. FACS analysis was performed to measure the
fluorescence intensity intracellularly and to determine whether the cyclic peptides are facilitating the
cargos to cross the membrane.
4.4.1. Mechanism of Cellular Uptake: Effect of Endocytic Inhibitors
Human breast carcinoma cells (MDA-MB-231) were grown in 6-well plates (5× 105 cells per well) in
complete media and then incubated in Opti-MEM. The cells were preincubated with different inhibitors.
Chloroquine (100 µM), chlorpromazine (30 µM), or methyl-β-cyclodextrin (2.5 mM) were incubated
with cells separately for 30 min followed by incubation with a peptide (25 µM)/phosphopeptide (5 µM)
complex for 3 h at 37 ◦C. To induce ATP depletion, the cells were incubated for 60 min with 0.5% of
75 mM sodium azide in Opti-MEM prior to the addition of the complex. Then, FACS was followed as
described above.
4.4.2. Fluorescence Microscopy
CCRF-CEM cells (30 µL of 3 × 106) were seeded with EMEM media overnight on a glass-bottom
culture dish. The cells were treated with peptides (25 µM) + F′-GpYEEI (5 µM) in Opti-MEM and
incubated for 3 h at 37 ◦C. After 3 h incubation, cells were centrifuged at 800 rpm for 5 min. The
cells were then washed with 400 µL of PBS and centrifuged again. The media was then added to the
cells. The cells were then placed on the coverslip and were detected by using a Keyence fluorescence
microscope at 40×magnification (BZ-X700. Keyence Corp. of America, Itasca, IL, USA).
4.5. Statistical Analyses
To find the statistical significance of the cytotoxicity studies and uptake studies, an ANOVA test
was performed using a single factor in MS Excel 2016. For the cytotoxicity assay, cells with the medium
were used as control and compared with cells treated with the highest concentration of peptide. In
the case of the uptake studies, drug-treated cells were considered as a control and compared with
a drug/vehicle combination. A p value below 0.05 was considered significant for all analyses and
incorporated in the figures.
Supplementary Materials: The following are available online. The MALDI spectra, analytical HPLC, NMR of
selected compounds, and Ellman’s reagent reaction are provided.
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